 |
12 Products |  |
51 Diseases | | 12 Products |
|
10 Trials |  |
1329 News |  |
| «12...567891011121314151617» |
- Olysio (simeprevir) / J&J, Medivir
New P1 trial: A Crossover Study to Evaluate Relative Bioavailability of Simeprevir Age-appropriate Oral Formulation Candidates Compared With 150-milligram (mg) Oral Capsule in Healthy Adult Participants (clinicaltrials.gov) - Mar 11, 2015
P1, N=48, Not yet recruiting, Sponsor: Janssen Sciences Ireland UC
- ||| Olysio (simeprevir) / J&J, Medivir
Enrollment change: COMMIT: A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants (clinicaltrials.gov) - Mar 7, 2015
P2, N=250, Recruiting, Sponsor: Janssen-Cilag International NV
N=110 --> 250
- || samatasvir (IDX719) / Merck (MSD)
Trial primary completion date: Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) (clinicaltrials.gov) - Mar 3, 2015
P2, N=143, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=110 --> 250 Trial primary completion date: Jun 2014 --> Apr 2015
- ||| Olysio (simeprevir) / J&J, Medivir
Enrollment closed, Combination therapy: An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection (clinicaltrials.gov) - Feb 6, 2015
P2, N=63, Active, not recruiting, Sponsor: Janssen-Cilag International NV
Trial primary completion date: Jun 2014 --> Apr 2015 Recruiting --> Active, not recruiting
- |||| Olysio (simeprevir) / J&J, Medivir
Enrollment open: COMMIT: A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants (clinicaltrials.gov) - Feb 5, 2015
P2, N=110, Recruiting, Sponsor: Janssen-Cilag International NV
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- birinapant (IGM-9427) / IGM Biosciences
Trial primary completion date, Metastases: Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer (clinicaltrials.gov) - Feb 3, 2015
P2, N=11, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2014 --> Dec 2013
- | Olysio (simeprevir) / J&J, Medivir
Enrollment change, Trial primary completion date: An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant (clinicaltrials.gov) - Jan 30, 2015
P2, N=45, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
Trial primary completion date: Apr 2014 --> Dec 2013 N=69 --> 45 | Trial primary completion date: May 2016 --> Oct 2015
- ||||| Olysio (simeprevir) / J&J, Medivir
New P2 trial: ACCORDION-1: Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection (clinicaltrials.gov) - Jan 28, 2015
P2, N=90, Recruiting, Sponsor: Janssen Research & Development, LLC
- | Olysio (simeprevir) / J&J, Medivir
Enrollment open, Combination therapy: Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection (clinicaltrials.gov) - Jan 26, 2015
P3, N=40, Recruiting, Sponsor: Janssen R&D Ireland
N=69 --> 45 | Trial primary completion date: May 2016 --> Oct 2015 Not yet recruiting --> Recruiting
- |||| TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
Trial completion, Trial primary completion date, Combination therapy: A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus (clinicaltrials.gov) - Jan 26, 2015
P2a, N=90, Completed, Sponsor: Janssen R&D Ireland
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Sep 2014
- | birinapant (IGM-9427) / IGM Biosciences
Enrollment closed, Trial primary completion date, Combination therapy: Birinapant With 5-azacitidine in MDS Subjects Who Are Na (clinicaltrials.gov) - Jan 22, 2015
P1/2, N=45, Active, not recruiting, Sponsor: TetraLogic Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Sep 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> May 2015
- ||| adafosbuvir (AL-335) / J&J, Medivir
New P1 trial: First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 (clinicaltrials.gov) - Jan 15, 2015
P1, N=70, Recruiting, Sponsor: Alios Biopharma Inc.
- |||| Olysio (simeprevir) / J&J, Medivir
Enrollment open, Combination therapy: An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection (clinicaltrials.gov) - Jan 15, 2015
P2, N=60, Recruiting, Sponsor: Janssen-Cilag International NV
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> May 2015 Not yet recruiting --> Recruiting
- birinapant (IGM-9427) / IGM Biosciences
Trial completion: A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 15, 2015
P1/2, N=37, Completed, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||| remetinostat (SHP-141) / Medivir
Enrollment open, Epigenetic controller: Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma (clinicaltrials.gov) - Jan 13, 2015
P2, N=60, Recruiting, Sponsor: TetraLogic Pharmaceuticals
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Olysio (simeprevir) / J&J, Medivir
Trial primary completion date: A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection (clinicaltrials.gov) - Jan 13, 2015
P3, N=232, Active, not recruiting, Sponsor: Janssen-Cilag International NV
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2014 --> Aug 2015
- velpatasvir (GS-5816) / Gilead, Daklinza (daclatasvir) / BMS, Exviera (dasabuvir) / AbbVie
Clinical: GEHEP: Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions (clinicaltrials.gov) - Jan 7, 2015
P=N/A, N=210, Recruiting, Sponsor: Valme University Hospital
- | Olysio (simeprevir) / J&J, Medivir
Enrollment open: SMV + SOF With/Without RBV for IFN-II Patients With CHC (clinicaltrials.gov) - Jan 2, 2015
P4, N=40, Recruiting, Sponsor: SC Liver Research Consortium, LLC
Trial primary completion date: Oct 2014 --> Aug 2015 Not yet recruiting --> Recruiting
- ||||||| Olysio (simeprevir) / J&J, Medivir
Trial completion: An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients (clinicaltrials.gov) - Dec 17, 2014
P3, N=458, Completed, Sponsor: Janssen R&D Ireland
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- birinapant (IGM-9427) / IGM Biosciences
Enrollment open: Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B (clinicaltrials.gov) - Dec 11, 2014
P1, N=48, Recruiting, Sponsor: TetraLogic Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Olysio (simeprevir) / J&J, Medivir
Enrollment change, Trial withdrawal, Trial primary completion date, Metastases: A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C (clinicaltrials.gov) - Nov 25, 2014
P4, N=0, Withdrawn, Sponsor: University of California, San Francisco
Not yet recruiting --> Recruiting N=20 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2015 --> Nov 2014
- | birinapant (IGM-9427) / IGM Biosciences
New P1 trial: Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B (clinicaltrials.gov) - Nov 12, 2014
P1, N=48, Not yet recruiting, Sponsor: TetraLogic Pharmaceuticals
- ||||| Olysio (simeprevir) / J&J, Medivir
New P2 trial, Combination therapy: An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection (clinicaltrials.gov) - Oct 30, 2014
P2, N=60, Not yet recruiting, Sponsor: Janssen-Cilag International NV
- ||||| Olysio (simeprevir) / J&J, Medivir
Enrollment closed: A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection (clinicaltrials.gov) - Oct 23, 2014
P3, N=228, Active, not recruiting, Sponsor: Janssen-Cilag International NV
N=20 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2015 --> Nov 2014 Recruiting --> Active, not recruiting
- ||||| Olysio (simeprevir) / J&J, Medivir
New P2 trial: COMMIT: A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants (clinicaltrials.gov) - Oct 20, 2014
P2, N=110, Not yet recruiting, Sponsor: Janssen-Cilag International NV
- birinapant (IGM-9427) / IGM Biosciences, conatumumab (AMG 655) / Amgen
Trial primary completion date, Combination therapy: Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer (clinicaltrials.gov) - Oct 15, 2014
P1, N=40, Recruiting, Sponsor: TetraLogic Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2014 --> Apr 2015
- | Olysio (simeprevir) / J&J, Medivir
New P2 trial: An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease (clinicaltrials.gov) - Oct 15, 2014
P2, N=40, Recruiting, Sponsor: Janssen Research & Development, LLC
- ||| Olysio (simeprevir) / J&J, Medivir
New P3 trial, Combination therapy: Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection (clinicaltrials.gov) - Oct 4, 2014
P3, N=40, Not yet recruiting, Sponsor: Janssen R&D Ireland
- | Olysio (simeprevir) / J&J, Medivir
New P2 trial, Combination therapy: Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection (clinicaltrials.gov) - Oct 2, 2014
P2, N=30, Not yet recruiting, Sponsor: Peter J. Ruane, M.D.
- |||| Olysio (simeprevir) / J&J, Medivir
Enrollment open: An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant (clinicaltrials.gov) - Oct 2, 2014
P2, N=69, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
Trial primary completion date: Sep 2014 --> Apr 2015 Not yet recruiting --> Recruiting
- | Olysio (simeprevir) / J&J, Medivir
Trial completion: A Study to Examine the Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of TMC435 in Healthy Chinese Participants (clinicaltrials.gov) - Sep 30, 2014
P1, N=32, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||| Olysio (simeprevir) / J&J, Medivir
New P3 trial, Combination therapy: Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection (clinicaltrials.gov) - Sep 28, 2014
P3, N=40, Not yet recruiting, Sponsor: Janssen Infectious Diseases BVBA
- | Olysio (simeprevir) / J&J, Medivir
Enrollment closed: A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation (clinicaltrials.gov) - Sep 9, 2014
P2, N=35, Active, not recruiting, Sponsor: Janssen R&D Ireland
Recruiting --> Completed Recruiting --> Active, not recruiting
- | samatasvir (IDX719) / Merck (MSD)
Trial completion: Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007) (clinicaltrials.gov) - Aug 29, 2014
P1, N=34, Completed, Sponsor: Idenix Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | samatasvir (IDX719) / Merck (MSD)
Trial completion, Trial primary completion date: Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004) (clinicaltrials.gov) - Aug 29, 2014
P1, N=42, Completed, Sponsor: Idenix Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Apr 2013 --> Jul 2013
- || Olysio (simeprevir) / J&J, Medivir
Trial primary completion date: An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant (clinicaltrials.gov) - Aug 15, 2014
P2, N=69, Not yet recruiting, Sponsor: Janssen Scientific Affairs, LLC
Active, not recruiting --> Completed | Trial primary completion date: Apr 2013 --> Jul 2013 Trial primary completion date: Jul 2015 --> May 2016
- | Olysio (simeprevir) / J&J, Medivir
Enrollment change: A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation (clinicaltrials.gov) - Aug 15, 2014
P2, N=30, Recruiting, Sponsor: Janssen R&D Ireland
Trial primary completion date: Jul 2015 --> May 2016 N=40 --> 30
- Olysio (simeprevir) / J&J, Medivir
New P4 trial: SMV + SOF With/Without RBV for IFN-II Patients With CHC (clinicaltrials.gov) - Aug 12, 2014
P4, N=0, Not yet recruiting, Sponsor: SC Liver Research Consortium, LLC
- ||||| remetinostat (SHP-141) / Medivir
New P2 trial, Epigenetic controller: Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma (clinicaltrials.gov) - Aug 12, 2014
P2, N=60, Not yet recruiting, Sponsor: TetraLogic Pharmaceuticals
- | remetinostat (SHP-141) / Medivir
Trial completion, Enrollment change, Trial primary completion date, Epigenetic controller: Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL) (clinicaltrials.gov) - Aug 11, 2014
P1, N=18, Completed, Sponsor: TetraLogic Pharmaceuticals
N=40 --> 30 Active, not recruiting --> Completed | N=48 --> 18 | Trial primary completion date: Mar 2014 --> Sep 2013
- | Olysio (simeprevir) / J&J, Medivir
New P4 trial, Metastases: A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C (clinicaltrials.gov) - Aug 1, 2014
P4, N=20, Not yet recruiting, Sponsor: University of California, San Francisco
- ||| TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
Enrollment closed, Combination therapy: A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus (clinicaltrials.gov) - Jul 27, 2014
P2a, N=90, Active, not recruiting, Sponsor: Janssen R&D Ireland
Active, not recruiting --> Completed | N=48 --> 18 | Trial primary completion date: Mar 2014 --> Sep 2013 Recruiting --> Active, not recruiting
- | Adasuve (staccato loxapine) / AOP Orphan Pharma, Teva, Ferrer International, Galen, Medivir
New P1 trial: Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication (clinicaltrials.gov) - Jul 10, 2014
P1, N=30, Recruiting, Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.
- || TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
Trial primary completion date, Combination therapy: A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus (clinicaltrials.gov) - Jun 27, 2014
P2a, N=86, Recruiting, Sponsor: Janssen R&D Ireland
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2015 --> Jan 2015
- |||| birinapant (IGM-9427) / IGM Biosciences
Enrollment open: Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL (clinicaltrials.gov) - Jun 24, 2014
P2, N=158, Recruiting, Sponsor: TetraLogic Pharmaceuticals
Trial primary completion date: Aug 2015 --> Jan 2015 Not yet recruiting --> Recruiting
- | Olysio (simeprevir) / J&J, Medivir
New P4 trial: The SIM-SOF Trial for Hepatitis C (clinicaltrials.gov) - Jun 22, 2014
P4, N=82, Active, not recruiting, Sponsor: Center For Hepatitis C, Atlanta, GA
- ||||| Olysio (simeprevir) / J&J, Medivir
New P2 trial: An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant (clinicaltrials.gov) - Jun 18, 2014
P2, N=69, Not yet recruiting, Sponsor: Janssen Scientific Affairs, LLC
- Olysio (simeprevir) / J&J, Medivir
Enrollment open: A Study to Examine the Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of TMC435 in Healthy Chinese Participants (clinicaltrials.gov) - Jun 18, 2014
P1, N=32, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | GSK 2336805 / J&J, Olysio (simeprevir) / J&J, Medivir
Trial completion: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants. (clinicaltrials.gov) - Jun 18, 2014
P1, N=48, Completed, Sponsor: Janssen R&D Ireland
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Olysio (simeprevir) / J&J, Medivir
Phase classification, Combination therapy: PILLAR: A Study of TMC435 in Combination With Pegylated Interferon AlpFa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment (clinicaltrials.gov) - Jun 17, 2014
P2b, N=386, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Active, not recruiting --> Completed Phase classification: P2 --> P2b